John D. Mendlein's most recent trade in Fate Therapeutics Inc was a trade of 55,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Fate Therapeutics Inc | John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 55,000 | 55,000 | - | - | Stock Option (Right to Buy) | |
| Omega Therapeutics Inc | John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2024 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Omega Therapeutics Inc | John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 18,118 | 18,118 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | John D. Mendlein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jan 2023 | 28,461 | 0 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | John D. Mendlein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.37 per share. | 19 Jan 2023 | 28,461 | 311,231 (0%) | 0% | 1.4 | 38,992 | Common Stock |
| Fate Therapeutics Inc | John D. Mendlein | Director | Purchase of securities on an exchange or from another person at price $ 5.67 per share. | 11 Jan 2023 | 88,048 | 246,139 (0%) | 0% | 5.7 | 499,232 | Common Stock |
| Fate Therapeutics Inc | John D. Mendlein | Director | Purchase of securities on an exchange or from another person at price $ 5.43 per share. | 11 Jan 2023 | 36,631 | 282,770 (0%) | 0% | 5.4 | 198,906 | Common Stock |
| Fate Therapeutics Inc | John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 11,893 | 11,893 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 8,650 | 166,741 (0%) | 0% | 0 | Common Stock | |
| Omega Therapeutics Inc | John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2022 | 18,118 | 18,118 | - | - | Option (Right to Buy) | |
| Fate Therapeutics Inc | John D. Mendlein | Director | Sale of securities on an exchange or to another person at price $ 22.79 per share. | 03 Jun 2022 | 1,364 | 158,091 (0%) | 0% | 22.8 | 31,086 | Common Stock |
| Fate Therapeutics Inc | John D. Mendlein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2022 | 31,562 | 0 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | John D. Mendlein | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.63 per share. | 10 Mar 2022 | 31,562 | 191,017 (0%) | 0% | 1.6 | 51,446 | Common Stock |
| Fate Therapeutics Inc | John D. Mendlein | Director | Sale of securities on an exchange or to another person at price $ 34.73 per share. | 10 Mar 2022 | 19,493 | 171,524 (0%) | 0% | 34.7 | 676,992 | Common Stock |
| Fate Therapeutics Inc | John D. Mendlein | Director | Sale of securities on an exchange or to another person at price $ 35.48 per share. | 10 Mar 2022 | 12,069 | 159,455 (0%) | 0% | 35.5 | 428,208 | Common Stock |
| Fate Therapeutics Inc | John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 4,334 | 4,334 | - | - | Stock Option (Right to Buy) | |
| Fate Therapeutics Inc | John D. Mendlein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jun 2021 | 2,681 | 159,455 (0%) | 0% | 0 | Common Stock |